Canopy Biosciences takes in $2.4 mln Series A
St. Louis, Missouri-based Canopy Biosciences, a research tools company focusing on gene editing and expression analysis, has raised $2.4 million in Series A funding. BioGenerator, the investment arm of BioSTL, and Kingdom Capital led the round.
22 May 2018•1 min read
